COVID-19

Pulmonary and Cardiac Pathology in Covid-19: The First Autopsy Series from New Orleans
Authors report on the relevant cardiopulmonary findings in the first series of autopsies in the United States, with the cause of death being due to SARS-CoV-2 infection. These cases identify key pathologic states potentially contributing to severe disease and decompensation in these patients.

Co-detection of respiratory pathogens in patients hospitalized with Coronavirus | Loss of smell and taste in combination with other symptoms is a strong predictor of COVID-19 infection

Tiger at New York’s Bronx Zoo Tests Positive for Coronavirus | Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know

Virological assessment of hospitalized patients with COVID-2019 | Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial | Control the Contagion – Videos about the SARS-CoV-2 outbreak filmed by actors of Contagion

Covid-19 in Critically Ill Patients in the Seattle Region — Case Series | FDA approved drugs with broad anti-coronaviral activity inhibit SARS-CoV-2 in vitro

By Dickson Despommier —
The sign reads: “Wet Paint. Please Do Not Touch”. Yet despite this simple warning, when we encounter one, what is the first thing we do? The next thing we look for is a rag to wipe off the tell-tale evidence of our misguided skepticism. We even have an expression for such events: “Curiosity killed the cat but satisfaction brought it back”.

The feasibility of convalescent plasma therapy in severe COVID-19 patients | Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up

Clinical Reports: Characteristics of Infected Children in Hubei, Case-fatality rate and characteristics of patients in Italy, functional exhaustion of antiviral lymphocytes
Antiviral Therapeutics: FDA approval for plasma treatment, convalescent sera option

Clinical: China retrospectives |
Therapies: Lopinavir-Ritonavir, Hydroxychoroquine and Azithromycin trials | Epidemiology: Non-pharmaceutical interventions, cryptic transmission | Environmental: Aerosol and surface stability